Financiere de Tubize SA
LSE:0D53
Financiere de Tubize SA
LSE:0D53
Price:
61.8 EUR
0.16%
Market Closed
Updated:
May 11, 2024
EV/FCFF
Enterprise Value to FCFF
Enterprise Value to FCFF
-12 611.6
Current
-3 031
Median
18.1
Industry
Lower
than median
Lower
than industry value
Enterprise Value to Free Cash Flow To Firm (EV/FCFF) ratio is a valuation multiple that compares the value of a company, debt included, to the amount of free cash flow available for all stakeholders. This metric is very similar to the EV/OCF but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures (CapEx) from a company's operating cash flow.
EV/FCFF
=-12 611.6
Enterprise Value
/
4.3B
FCFF
-338k
All Countries
| Market Cap | EV/FCFF | ||||
|---|---|---|---|---|---|
| BE |
|
Financiere de Tubize SA
LSE:0D53
|
4.3B EUR | -12 611.6 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -15 979 072.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
722.3B USD | -191 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
3.9T DKK | 78.4 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 13 236.9 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
360.8B USD | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
329.4B USD | 32.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
191.8B GBP | 415.9 | |
| CH |
|
Novartis AG
SIX:NOVN
|
180.6B CHF | 20.2 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
179.5B CHF | 37.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
158.1B USD | 44.9 |
EV/FCFF Forward Multiples
Forward EV/FCFF multiple is a version of the EV/FCFF ratio that uses forecasted free cash flow to firm for the EV/FCFF calculation. 1-Year, 2-Years, and 3-Years forwards use free cash flow to firm forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/FCFF
N/A
2-Years Forward
EV/FCFF
N/A
3-Years Forward
EV/FCFF
N/A
You don't have any saved screeners yet
